- Home
- ALIS vs HURA Comparison
ALIS vs HURA Comparison
Compare ALIS & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ALIS | HURA |
|---|---|---|
| Founded | 2024 | 2009 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.9M | 87.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ALIS | HURA |
|---|---|---|
| Price | $9.98 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 7.3K | ★ 779.3K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $0.41 |
| 52 Week High | $10.07 | $4.41 |
Technical Indicators
Market Signals| Indicator | ALIS | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 63.26 |
| Support Level | $9.96 | $1.56 |
| Resistance Level | $10.03 | $2.20 |
| Average True Range (ATR) | 0.01 | 0.20 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 28.57 | 62.65 |
Price Performance
Historical ComparisonAbout ALIS Calisa Acquisition Corp Ordinary shares
Calisa Acquisition Corp is a blank check company with the purpose of effecting a merger, asset acquisition, stock exchange, stock purchase, reorganization, or similar business combination.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.